4//SEC Filing
SUNESIS PHARMACEUTICALS INC 4
Accession 0001181431-09-049710
$VIRXCIK 0001061027operating
Filed
Nov 2, 7:00 PM ET
Accepted
Nov 3, 4:52 PM ET
Size
10.0 KB
Accession
0001181431-09-049710
Insider Transaction Report
Form 4
TRAINOR III EUGENE A
10% Owner
Transactions
- Purchase
Common Stock Warrant (Right to Buy)
2009-10-30+3,331,660→ 3,331,660 total(indirect: See Note 1)Exercise: $0.22From: 2009-10-30Exp: 2016-10-30→ Common Stock (3,331,660 underlying) - Purchase
Series A Preferred Stock
2009-10-30+333,166→ 999,499 total(indirect: See Note 1)→ Common Stock (3,331,660 underlying)
Footnotes (4)
- [F1]The Reporting Person is a manager of NEA 12 GP, LLC, the sole general partner of NEA Partners 12, Limited Partnership ("NEA Partners 12"). NEA Partners 12 is the sole general partner of New Enterprise Associates 12, Limited Partnership ("NEA 12"). NEA 12 is the sole member of Growth Equity Opportunities, LLC ("GEO"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "1934 Act"), or otherwise of such portion of the securities of the issuer held by GEO in which the Reporting Person has no pecuniary interest therein.
- [F2]Each share of Series A Preferred Stock is initially convertible into 10 shares of common stock, subject to adjustment for any stock dividends, combinations, stock splits, recapitalizations and the like. The Series A Preferred Stock is convertible at the election of the holder at any time after the earlier of (i) the closing of a qualifying alternative common stock financing (as defined in the applicable Certificate of Designation), or (ii) January 24, 2011.
- [F3]All outstanding shares of Series A Preferred Stock would be automatically converted into shares of common stock upon the earlier to occur of: (i) the affirmative election of the holders of at least a majority of the outstanding shares of the Series A Preferred Stock; (ii) the date, following the closing of a qualifying alternative common stock financing (as defined in the applicable Certificate of Designation), on which the closing bid price for the common stock has been equal to or at least $0.66 per share for a period of thirty trading days with an average trading volume during such period of at least 200,000 shares; or (iii) the common equity closing (as defined in the applicable Certificate of Designation).
- [F4]The Series A Preferred Stock has no expiration date.
Documents
Issuer
SUNESIS PHARMACEUTICALS INC
CIK 0001061027
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001061027
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 7:00 PM ET
- Accepted
- Nov 3, 4:52 PM ET
- Size
- 10.0 KB